Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M370Revenue (TTM) $M162Net Margin (%)-34.2Altman Z-Score0.3
Enterprise Value $M302EPS (TTM) $-0.8Operating Margin %-29.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-34.4Higher ROA y-yN
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio3.6Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %--Current Ratio3.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-12.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-24.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M80.6ROIC % (ttm)-26.3Gross Margin Increase y-yN

Gurus Latest Trades with SPPI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SPPIJoel Greenblatt 2016-09-30 Sold Out $4.47 - $7.1
($5.92)
$ 4.60-22%Sold Out0
SPPIBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Buy $4.47 - $7.1
($5.92)
$ 4.60-22%New holding238,988
SPPIJoel Greenblatt 2016-06-30 Buy $6.33 - $7.65
($7.06)
$ 4.60-35%New holding39,070
SPPIJoel Greenblatt 2012-12-31 Sold Out -0.02%$10.64 - $12.31
($11.39)
$ 4.60-60%Sold Out0
SPPIJoel Greenblatt 2012-09-30 Buy 0.02%$11.6 - $17.05
($13.85)
$ 4.60-67%New holding19,901
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SPPI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SPPI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MAIDA ANTHONY E IIIDirector 2013-03-05Sell5,000$11.5-60view
MAIDA ANTHONY E IIIDirector 2013-02-05Sell5,000$12.25-62.45view
MAIDA ANTHONY E IIIDirector 2013-01-02Sell5,000$11.42-59.72view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-12-31Sell378,343$11.29-59.26view
MAIDA ANTHONY E IIIDirector 2012-12-04Sell5,000$11.65-60.52view
Keller Joseph KennethEVP & COO 2012-11-12Buy10,000$10.95-57.99view
MAIDA ANTHONY E IIIDirector 2012-11-01Sell5,000$11.09-58.52view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-10-09Sell11,350$12.5-63.2view
MAIDA ANTHONY E IIIDirector 2012-10-02Sell5,000$11.8-61.02view
Scott Brett LActing CFO 2012-10-01Sell6,000$12-61.67view

Quarterly/Annual Reports about SPPI:

News about SPPI:

Articles On GuruFocus.com
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : January 20, 2017 Jan 20 2017
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
Is Steel Partners Holdings LP (SPLP) A Good Stock To Buy According To Other Hedge Funds? Dec 20 2016
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : December 14, 2016 Dec 14 2016
Should You Avoid Spectrum Pharmaceuticals, Inc. (SPPI)? Dec 12 2016
Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer... Dec 08 2016
Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer... Dec 08 2016
Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the... Dec 06 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at... Dec 05 2016
Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American... Dec 02 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Spectrum Pharmaceuticals, Inc. for... Nov 29 2016
Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SPPI-US :... Nov 29 2016
ETFs with exposure to Spectrum Pharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
SPECTRUM PHARMACEUTICALS INC Financials Nov 23 2016
Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola Nov 23 2016
Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22,... Nov 22 2016
Spectrum Bladder Cancer Drug Nixed by FDA (SPPI) Nov 21 2016
Spectrum (SPPI) Gets CRL for Bladder Cancer Drug in U.S. Nov 21 2016
3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Spectrum... Nov 18 2016
SPPI UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action... Nov 18 2016
Spectrum Pharma says U.S. FDA rejects its bladder cancer drug Nov 18 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 18 2016
Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference... Nov 17 2016
Spectrum Pharmaceuticals Provides Third Quarter Financial Update Nov 14 2016
Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update Nov 03 2016
Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results Teleconference and Webcast Oct 27 2016
FDA Advisory Committee Votes that Qapzola™ (apaziquone) Has Not Shown Substantial Evidence of a... Sep 14 2016
Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update Aug 09 2016
Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference and Webcast Aug 02 2016
Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation Jul 13 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald's 2nd Annual... Jul 06 2016
Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of... Jun 09 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on... Jun 01 2016
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update May 05 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016... May 03 2016
Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast Apr 28 2016
Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel,... Jan 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)